Portfolio

Ambrilia Biopharma Inc. (TSX:AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. The Company’s strategy aims to capitalize on its broad portfolio and original expertise in virology. Ambrilia’s product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery technology for cancer, HIV protease, integrase and entry inhibitors, HCV entry and polymerase inhibitors and Anti-Influenza A compounds.

Industry :	Science de la vie
Location :	Verdun, Québec
Funds :	Innoven FCPI 1998, 1999, 2000, 2001, 2003. Innoven Europe. Poste Innovation 1, 2, 3, 5, 6, 9. La Banque Postale Innovation 1.
Contact:	Jean-Sébastien Cleiftie